Issue link: https://www.e-digitaleditions.com/i/1546950
This section provides information that may be useful in research and development or manufacturing. Content is provided by the organizations listed. No endorsement or preference is intended. 34 OctOber 2026 Inhalation SPECIAL SECTION Outsourcing Services This section of Inhalation provides information that may be useful in research and development or manufacturing. Content is provided by the companies listed. No product endorsement or preference is intended. Next-generation inhaled and nasal drug-device product development Bespak, the specialist CDMO for inhaled and nasal drug delivery, supports every stage of drug- device development and supply including pressurized metered dose inhalers (pMDIs), valves, dry powder inhalers (DPIs), soft mist inhalers (SMIs) and unit- dose, multi-dose, liquid, powder and soft mist nasal delivery devices. Meeting the sector's growing sustain- ability demands, Bespak provides end-to-end devel- opment of low carbon pMDIs, with manufacturing capabilities at lab, pilot and commercial scales, as well as compatible components. rough a strategic col- laboration with Upperton, Bespak also delivers an integrated nasal product development service, allow- ing formulations and delivery devices to be consid- ered together from an early stage. Bespak United Kingdom enquiries@bespak.com www.bespak.com Fast to clinic formulation platform for DPI products Intertek's new partnership with CrystecPharma sup- ports global clients in accelerating development time- lines for inhaled medicines, particularly dry powder inhalers (DPIs). A "fast to clinic" platform can enable rapid product development from the initial formu- lation concept to GMP clinical manufacturing in less than half the time typically required. is highly agile capability can allow clients aiming to formulate new small or large (biologic) molecules, or repurpose existing active pharmaceutical ingredients, to benefit from technology that enables new forms of molecules and novel particles to be manufactured in ways that greatly enhance their therapeutic performance. Intertek Pharmaceutical Services UK: +44 1763 261648 bd.melbourn@intertek.com www.intertek.com

